ARNA Genomics, an innovative biotechnology company specializing in the development and implementation of diagnostic methods for the early detection of cancer, is five years old.
Our mission is to increase life expectancy and significantly reduce mortality due to the widespread introduction of new, unmatched screening methods, early diagnostics and monitoring of cancer treatment worldwide.
Working in the field of “liquid biopsy“, since its foundation in 2013, the company has developed not only a unique technology for detecting the biological signs of the most frequently occurring oncological diseases in the blood plasma at the earliest stages, but also introduced its first product, the genetic an early detection test for breast cancer – ARNA Breast.
Director General and founder of ARNA Genomics Egor Melnikov noted that in the first five years the company has come a long way: from the idea to creating a final high-tech product that can be of considerable benefit, both in mass screening studies of women, especially at risk groups, and in early detection of cancer mammary gland.
The genetic test of ARNA Breast is the analysis of blood plasma for detection of fragments of oncogenes in circulating extracellular DNA for the purpose of early detection of breast cancer with high accuracy. Sensitivity and specificity of the test, obtained in experimental works, are close to 95% and exceed by these parameters all known methods of diagnosing cancer to date.
Noting the success of the rapid development of the company, the well-known molecular biologist Charles Cantor (USA) stressed: “The future of cancer diagnosis at an early stage in the next 10 years belongs to the” liquid biopsy “. The main question is only which companies and methods will dominate in this area. I have every reason to believe that ARNA Genomics has found effective and inexpensive approaches to this problem, and it is destined to become one of the leaders in this important field. “
Currently, the company conducts a number of biomedical research in clinics of the leading research centers of the Russian Federation: Sechenov University and NMI of Oncology named after. Petrova. The results of these studies will be available this fall.